रैंकिंग पर वापस जाएं

Aptargroup Inc (ATR)

Fair Value
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

66

मूल्य

$121.37

मार्केट कैप

$7.91B

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users

P/E: 47.5Score: 72Market cap: $26.44B

It supplies the elastomeric stoppers, seals and injection delivery systems that compete head-on with Aptar Pharma's injectables business for the same drug makers.

Silgan Holdings Inc.SLGN

Through Silgan Dispensing Systems it makes the same pumps, trigger sprayers and dispensing closures Aptar sells to beauty, home care and food and beverage brands.

Nemera (Financière N)Not tracked

This French maker of nasal sprays, preservative-free eyedroppers and inhalers bids for the same drug-delivery device contracts with pharmaceutical companies as Aptar Pharma.

Gerresheimer AGGXI

The German group sells inhalers, pen injectors and primary pharmaceutical packaging, and also cosmetics packaging, to the same pharma and beauty customers Aptar serves in Europe and the United States.

Amcor plcAMCR

After absorbing Berry Global in April 2025 it is a large supplier of closures, dispensing components and healthcare packaging to the consumer and pharmaceutical brands Aptar depends on.

Bericap GmbH & Co. KGNot tracked

The privately held German closure specialist competes with Aptar's Food + Beverage segment on dispensing and non-dispensing plastic caps for drinks, edible oils and household liquids.

बैलेंस शीट और तरलता

राजस्व

$3.93B

पिछले 12 महीने (30/6/2026 तक)

शुद्ध आय

$363M

पिछले 12 महीने (30/6/2026 तक)

Free Cash Flow

$300M

कुल इक्विटी

$2.67B

कुल देनदारियाँ

$2.57B

Current Ratio

1.61

Interest Coverage

7.52

Debt/EBITDA

1.79

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

सामान्य मामलाउचित मूल्यांकित

Fair Value

$154.38

वर्तमान मूल्य

$121.37

Margin of Safety

+21.4%

Fair Value सीमा

$116.80 - $191.96

इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।

अनुमान विधियाँ

विश्लेषकों का लक्ष्य मूल्य:$170.14
डिस्काउंटेड कैश फ्लो (DCF):$195.10
आय गुणक (P/E):$113.97
Graham वृद्धि फॉर्मूला:$167.32
अर्निंग पावर वैल्यू (EPV):$77.49
उचित P/B:$99.33
लाभांश डिस्काउंट (Gordon):$48.06
P/FFO, परिचालन से प्राप्त निधि:$171.16
मध्य-चक्र आय:$142.41
राजस्व गुणक:$241.35
विश्लेषक सहमति:दृढ़ खरीदें (10B / 2H / 0S)
अंतिम Earnings सरप्राइज़:+3.82%

मूल्यांकन मेट्रिक्स

P/E Ratio

21.91

ROE

14.7%

P/B Ratio

2.93

P/FCF

24.82

Gross Margin

-

ROIC

9.4%

लाभप्रदता Radar

मूल्य सृजन (प्रतिस्पर्धी बढ़त)

ROIC

9.4%

WACC

7.2%

ROIC − WACC

+2.2 pp

ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।

Fundamental विश्लेषण मानदंड

पास (21)

  • EPS shows upward trend
  • EPS CAGR 6.02%
  • Price CAGR 5.45%
  • ROIC 9.4%
  • P/FCF 24.82
  • P/B Ratio 2.93
  • Debt/Equity ratio
  • Operating Margin 12.1%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 13.6%
  • Revenue Growth 5Y 5.2%
  • Analyst Consensus 83% Buy
  • Earnings Surprise avg 4.0%
  • PEG Ratio 1.66
  • Earnings Quality (OCF/NI) 1.61
  • Share Dilution -1.5%
  • Piotroski F-Score 5/9

फेल (5)

  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Net Margin Trend 9.2% vs 10.8%

अनुपलब्ध (2)

  • Gross Margin NaN%
  • Dividend Payout NaN%

Piotroski F-Score

5/9

मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक

score
criteria

Earnings गुणवत्ता

1.61

उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित

शेयर Dilution

-1.5%

शेयर वापस खरीद रही है। शेयरधारक अनुकूल

संस्थागत होल्डिंग

इस कंपनी के लिए कोई संस्थागत घोषणा उपलब्ध नहीं है।

प्रशासन

कार्यकारी टीम

नामपदआयु
Mr. Gael TouyaCEO, President & Director55
Ms. Vanessa KanuExecutive VP & CFO47
Mr. Stephan B. TandaDirector & Advisor60
Mr. Marc PrieurPresident of Aptar Beauty59
Ms. Xiangwei GongExecutive VP of Strategic Group Development & President of Aptar Asia55
Mr. Hedi TliliPresident of Aptar Closures50
Mr. Aditya J. GandhiVP, Principal Accounting Officer & Chief Accounting Officer45
Ms. Mary SkafidasSenior Vice President of Investor Relations & Communications-
Ms. Irene HudsonExecutive VP, Chief Legal Officer & Corporate Secretary48
Ms. Shiela Pallerne VinczellerChief Human Resources Officer61

Audit जोखिम

1

बोर्ड जोखिम

1

मुआवजा जोखिम

2

शेयरधारक अधिकार जोखिम

5

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

दस्तावेज़

  • वार्षिक रिपोर्ट (10-K)

    कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।

    दाखिल तिथि: 2026-02-06

    दस्तावेज़ देखें
  • तिमाही रिपोर्ट (10-Q)

    पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।

    दाखिल तिथि: 2026-07-31

    दस्तावेज़ देखें
  • विशेष रिपोर्ट (8-K)

    किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।

    दाखिल तिथि: 2026-09-21

    दस्तावेज़ देखें

via SEC EDGAR

आय का इतिहास

via SEC EDGAR

Latest News

Recent headlines for ATR, sourced from Markets Gazette.

  • 28d agoPOSITIVE
    ATR (JV Leonardo-Airbus), maxi ordine da 1 miliardo di dollari dall'indiana FLY91

    Indian regional airline FLY91 has placed a landmark order for 40 ATR 72-600 aircraft, valued at approximately $1 billion. This significant deal represents the largest order for ATR globally from a single airline. The ATR 72-600 is a turboprop regional airliner, and this order underscores FLY91's commitment to expanding its regional network. For investors in Leonardo (a partner in the ATR joint venture), this order signals strong demand for regional aircraft and a positive outlook for the turboprop market, potentially boosting future revenues and profitability.

  • 2/28/2026POSITIVE
    River Road Loads Up on ATR With 917,000 Shares in New Position

    River Road, a prominent investment manager, has announced the establishment of a new significant position in AptarGroup Inc., acquiring 917,000 shares. AptarGroup is a global provider of proprietary dispensing and sealing solutions for the healthcare, beauty, and consumer markets. This strategic move by River Road signals strong confidence in AptarGroup's future prospects, suggesting the company may be undervalued or poised for significant growth. Investors might interpret this as a bullish signal, indicating potential increased interest and demand for ATR shares, given its robust global market positioning.

via Markets Gazette

Disclaimer

यह प्लेटफ़ॉर्म केवल शैक्षिक उद्देश्यों के लिए है। यह कोई वित्तीय, निवेश, या ट्रेडिंग सलाह नहीं देता। सभी स्कोर, मूल्यांकन, और संकेत सार्वजनिक रूप से उपलब्ध डेटा के स्वचालित विश्लेषण पर आधारित हैं जो अधूरे या गलत हो सकते हैं। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और एक योग्य वित्तीय सलाहकार से परामर्श लें।

निर्मित द्वारा CODEPRESS s.r.l.